Oragenics, Inc. (OGEN) is a publicly traded company in the Healthcare — Biotechnology industry listed on AMEX. This overview shows the latest price, key valuation ratios, profitability metrics and financial-health indicators used by fundamental investors.
Oragenics, Inc. (OGEN) is a U.S.-based biotechnology firm primarily focused on creating treatments for infectious diseases. Among its pipeline assets are two vaccine candidates designed to combat the novel severe acute respiratory syndrome coronavirus (SARS-CoV-2): NT-CoV2-1, an intranasal formulation, and Terra CoV-2, an intramuscular option.
Analysis Summary
Trailing-twelve-month margins: gross margin 0.0%, operating margin 0.0%, net margin 0.0%.
At the current price of $0.50, OGEN has negative trailing earnings (P/E not meaningful) and an ROE of -144.23%. Market capitalisation stands at $2M.
Balance sheet quality for OGEN: current ratio of 5.6, net cash position of $8.2M. A debt-to-equity below 1.0 typically signals conservative capital structure, while a current ratio above 1.5 indicates comfortable short-term liquidity.
Price
| Price | $0.50 |
| Market Cap | $2M |
| Exchange | AMEX |
| Country | US |
Valuation Ratios
| Price / Book | 0.61 |
| EV / EBITDA | 0.22 |
| Dividend Yield | 0.00% |
Profitability
| Return on Equity | -144.23% |
| Return on Invested Capital | -279.54% |
| Return on Assets | -183.59% |
| Gross Margin | 0.00% |
| Operating Margin | 0.00% |
| Net Margin | 0.00% |
Financial Health
| Debt / Equity | 0.00 |
| Current Ratio | 3.01 |
What to look at in Biotech
Most small biotechs lose money. Analysing them with P/E makes no sense — look at cash and pipeline.
- Cash Runway — Months of cash at current burn rate. <18 months = urgent dilution risk
- Annual cash burn — Rate at which they burn operating cash. Compare with cash position to project runway
- Total Debt — Biotech with no revenue + debt = recipe for bankruptcy
- R&D / Market cap — How much they invest in pipeline vs the company value — research-intensity indicator
- Market cap / Cash — If it trades near its cash, the market assigns ~0 value to the pipeline — opportunity or trap
Peer Comparison
| Symbol | Company | Market Cap | P/E | P/B | ROE |
|---|---|---|---|---|---|
| OGEN | Oragenics, Inc. | $2M | 0.61 | -144.2% | |
| 0QZU.L | Vertex Pharmaceuticals Incorporated | $131.8B | |||
| VRTX | Vertex Pharmaceuticals Incorporated | $130.3B | 29.68 | 6.45 | 23.3% |
| 0R2M.L | Regeneron Pharmaceuticals, Inc. | $84.0B | |||
| REGN | Regeneron Pharmaceuticals, Inc. | $79.8B | 18.79 | 2.57 | 13.8% |
| ARGX | argenx SE | $61.2B | 36.30 | 7.40 | 21.7% |
| MRNA | Moderna, Inc. | $57.8B | 1.34 | -39.2% | |
| RVMD | Revolution Medicines, Inc. | $41.7B | 15.96 | -96.4% |
Price Performance
| 1 month | -8.42% |
| 3 months | -8.99% |
| Year-to-date | -36.16% |
| 1 year | -60.32% |
| 3 years | -99.46% |
| 5 years | -99.96% |
52-Week Range
| 52-week High | $1.45 |
| 52-week Low | $0.48 |
| Avg Volume (90d) | 39K |
Related companies: AIM · CANF · CNSP · ENSC · KALA · KZIA · QLGN
Explore sector: Healthcare · Biotechnology
More sections of OGEN: Financials · Valuation · Statistics · Estimates · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks